|Mr. Gary S. Titus||Chairman & Corp. Sec.||72.25k||N/A||1960|
|Dr. Anthony J. Gringeri Ph.D.||CEO, Pres & Director||368.99k||N/A||1953|
|Dr. John S. Yu M.D., Ph.D.||Founder & Director||N/A||N/A||1964|
|Mr. David E. Fractor CPA||Chief Financial Officer||202.5k||N/A||1960|
|Dr. Steven J. Swanson M.D., Ph.D.||Sr. VP of Research||313.57k||N/A||1956|
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.
ImmunoCellular Therapeutics, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.